Décrets, arrêtés, circulaires

TEXTES GÉNÉRAUX

MINISTÈRE DE L'ÉDUCATION NATIONALE, DE L'ENSEIGNEMENT SUPÉRIEUR ET DE LA RECHERCHE

RECHERCHE

Arrêté du 16 février 2005 portant autorisation d'importation de cellules souches embryonnaires humaines à des fins scientifiques en application des dispositions de l'article 37 de la loi nº 2004-800 du 6 août 2004 relative à la bioéthique

NOR : *RECR0500014A*

Par arrêté du ministre des solidarités, de la santé et de la famille et du ministre délégué à la recherche en date du 16 février 2005, l'Institut national de la santé et de la recherche médicale (U 421) est autorisé à importer auprès de la société Cellartis AB (Suède), dans les conditions décrites dans le dossier de demande d'autorisation, une lignée de cellules souches embryonnaires humaines Sahlgrenska 1 (SA-01) destinée à des recherches ayant pour finalité l'étude des potentialités de cellules neuronales obtenues à partir de cellules souches embryonnaires humaines dans le traitement de la maladie de Huntington.

January 8, 2009

Concerning research on human embryonic stem cells established at Sahlgrenska University Hospital:

Informed consent from the donating couples have been gained for stem cell line SA002 and SA001 were the IRB approval concerning the human embryonic stem cell lines applies (Dnr 067-04; Records from meeting April 14, 2004). SA002.5 is a subclone of SA002 and is therefore covered by the donor consent of SA002.

Summary of Donor Consent Details

Cell line nr.	Ethical approval from IRB	Establishment date	Date of first signed informed consent	Date of last signed informed consent	Boxes ticked in the last signed donor consent form		
					We permit that these stem cells are sent abroad for research purposes.	We do not permit that these stem cells are sent abroad for research purposes.	We wish to be contacted prior to any new research purpose.
SA001	Ö 507-00, Ö026-03, 067-04	2001-03-20	2001-03-06	2004-12-06	Yes	No	No
SA002	Ö 507-00, Ö026-03, 067-04	2001-05-21	2001-05-06	2004-11-27	Yes	No	No

Christina Bergh

Professor
Reproductive Medicine
Department of Obstetrics and Gynaecology
Institution of Clinical Sciences, Sahlgrenska Academy
Sahlgrenska University Hospital
S-413 45 GÖTEBORG
Sweden

Assurance of Conditions of Consent for human Embryonic Stem Cell lines SA001, SA002 and SA002.5 (Subclone of SA002)

As responsible for the stem cell program at Sahlgrenska University Hospital and for ensuring that the consent from the embryo donors whose embryos resulted in the derivation of the SA001, SA002 and SA002.5 (subclone of SA002 accordingly having the donor consent as SA002) human Embryonic Stem Cell (hESC) lines were obtained, I, Charles Hanson, Associate Professor Sahlgrenska University Hospital along with Lars Nilsson, Associate Professor attending physician at Sahlgrenska University Hospital at the time of donation, hereby provide the following written assurance that the embryos used for the derivation of the SA001 and SA002:

1. were created using in vitro fertilization for reproductive purposes and were no longer needed for this purpose;

2. were donated by individuals who sought reproductive treatment (hereafter referred to as "donor(s)") and who gave voluntary written consent for the human embryos to be used for research purposes.

Furthermore, during the consent process:

a. All options available in the health care facility where treatment was sought pertaining to the embryos no longer needed for reproductive purposes were explained to the individual(s) who sought reproductive treatment.

b. No payments, cash or in kind, were offered for the donated embryos.

c. Policies and/or procedures were in place at the health care facility where the embryos were donated that neither consenting nor refusing to donate embryos for research would affect the quality of care provided to potential donor(s).

d. There was a clear separation between the prospective donor(s)'s decision to create human embryos for reproductive purposes and the prospective donor(s)'s decision to donate human embryos for research purposes. Specifically:

    i. Decisions related to the creation of human embryos for reproductive purposes should have been made free from the influence of researchers proposing to

REGION VÄSTRA GÖTALAND

Sahlgrenska University Hospital
Clinical department of reproductive medicine
ADDRESS Blå Stråket 6, 413 45 Göteborg, Sweden
TELEPHONE +46 31 342 00 00

derive or utilize hESCs in research. The attending physician responsible for reproductive clinical care and the researcher deriving and/or proposing to utilize hESCs should not have been the same person unless separation was not practicable.

ii. At the time of donation, consent for that donation should have been obtained from the individual(s) who had sought reproductive treatment. That is, even if potential donor(s) had given prior indication of their intent to donate to research any embryos that remained after reproductive treatment, consent for the donation for research purposes should have been given at the time of the donation.

iii. Donor(s) should have been informed that they retained the right to withdraw consent for the donation of the embryo until the embryos were actually used to derive embryonic stem cells or until information which could link the identity of the donor(s) with the embryo was no longer retained, if applicable.

e. During the consent process, the donor(s) were informed of the following:
   i. that the embryos would be used to derive hESCs for research;
   ii. what would happen to the embryos in the derivation of hESCs for research;
   iii. that hESCs derived from the embryos might be kept for many years;
   iv. that the donation was to be carried out according to Swedish law on Discrimination SFS 2008:567 (This law replaces the Swedish law on equality (SFS 1991:433) and six other civil rights laws in force at the time of establishment.) Those laws do not allow discrimination, any restriction or direction regarding the individual(s) who may receive medical benefit from the use of the hESCs now or at the time of establishment. Additionally, referring to clinical matters such as who may be the recipients of cell transplants, hESC lines SA001 and SA002 where derived for research purposes only and are not for clinical use;
   v. that the research was not intended to provide direct medical benefit to the donor(s);
   vi. that the results of research using the hESCs would be carried out under Swedish law (at that time the Swedish law SFS 1991:115 , now replaced by the law on Genetic Integrity SFS 2006:351. This law allows commercialization of non-traceable (anonymous) human embryonic stem cell lines), and that the donor(s) would not receive financial or any other benefits from any such commercial development;
   vii. that the identity of the donor(s) would not be provided to researchers.

Sahlgrenska University Hospital
Clinical department of reproductive medicine
ADDRESS Blå Stråket 6, 413 45 Göteborg, Sweden
TELEPHONE +46 31 342 00 00

To the best of my knowledge, I, Charles Hanson, Associate Professor Sahlgrenska University Hospital along with Lars Nilsson , Associate Professor Sahlgrenska, attending physician at Sahlgrenska University Hospital at the time of donation, hereby certify that the above represents a true, accurate and complete description of the consent process used for the donation of the embryos which resulted in the derivation of the SA001 and SA002 human Embryonic Stem Cell lines. I am aware that any false, fictitious, or fraudulent statements or claims may subject me to criminal, civil, or administrative penalties (U.S. Code, Title 18, Section 1001).

Charles Hanson, Associate Professor Date 100129

Reproductive Medicine
Department of Obstretrics and Gynaecology
Institution of Clinical Sciences, Sahlgerenska Academy
Sahlgrenska University Hospital
S-413 45 GÖTEBORG
SWEDEN

Lars Nilsson, MD, Associate Professor Date 100129

Reproductive Medicine
Department of Obstretrics and Gynaecology
Institution of Clinical Sciences, Sahlgerenska Academy
Sahlgrenska University Hospital
S-413 45 GÖTEBORG
SWEDEN

This is a translation from the Swedish original presented, 2010-08-19

Sahlgrenska University Hospital 2001-02-23/Cpa
Division of Women's Health Care, Urology and Oncology

Patient information

Concerning culture of so-called stem cells from human fertilized eggs

In vitro fertilization (IVF) normally results in supernumerary fertilized eggs (embryos), i.e. more eggs are obtained than can be transferred back to the woman at the time of treatment. If those embryos are assessed as being normal they are frozen and can be transferred back to the woman at a later point of time if so desired. Embryos of poor quality which are therefore considered not suitable for transfer back to the woman, or which are assumed not to survive freezing (i.e non-viable embryos), are presently destroyed. However, these embryos can be of interest from a scientific point of view. Some of these embryos can be cultured for 5-6 days, and if cells are isolated from the cultured embryos during this period, those isolated cells may have the possibility to develop into various kinds of cells such as nerve cells, muscle cells, or different types of blood cells. We believe that in the future this kind of cell isolations may be part of future therapies for patients suffering from injuries (spinal cord injuries, joint damages) or diseases (e.g. heart attack).
In the present project we will only learn how to culture these cells for a longer time period. The project will only use fertilized eggs of poor quality that, if not used in this study, will be discarded. The cells will not be used for any clinical purpose. After the study is finalized the material will be destroyed. Your participation in this project with material to research is totally voluntary, and you can freely desist from donating material without this in any way influencing your treatment. You can also withdraw your participation in the project at any time.
The initiator of this study is Professor Lars Hamberger, who also is available to answer any questions that concern the embryonic stem cells, their risks and their potential for the future. Phone: 031 – 342 33 38 or e-mail:lars.hamberger@obgyn.gu.se

Further information can be obtained from

Lars Nilsson
Associate Professor
Phone: 031-342 2100, call7893

Christina Bergh
Associate Professor
Phone: 031-342 1000, call 7452

I have verbally been informed about the research and its content and I have taken part of the written information above. I am aware my participation is fully voluntary and that I whenever I wish can without any further explanation can take my donation back without this affecting my further treatment

Date ....

Signature ....

Clarification of signature..... .....

SAHLGRENSKA UNIVERSITY HOSPITAL
DIVISION; REPRODUCTIVE MEDICINE Phone 031-342 10 00 Fax: 031-82 92 48

This is a translation from the Swedish original presented, 2010-08-19

Sahlgrenska University Hospital
Division of Women's Health Care, Urology and Oncology

2001-02-23/Cpa

Patient information

Concerning culture of so-called stem cells from human fertilized eggs

In vitro fertilization (IVF) normally results in supernumerary fertilized eggs (embryos), i.e. more eggs are obtained than can be transferred back to the woman at the time of treatment. If those embryos are assessed as being normal they are frozen and can be transferred back to the woman at a later point of time if so desired. Embryos of poor quality which are therefore considered not suitable for transfer back to the woman, or which are assumed not to survive freezing (i.e non-viable embryos), are presently destroyed. However, these embryos can be of interest from a scientific point of view. Some of these embryos can be cultured for 5-6 days, and if cells are isolated from the cultured embryos during this period, those isolated cells may have the possibility to develop into various kinds of cells such as nerve cells, muscle cells, or different types of blood cells. We believe that in the future this kind of cell isolations may be part of future therapies for patients suffering from injuries (spinal cord injuries, joint damages) or diseases (e.g. heart attack).
In the present project we will only learn how to culture these cells for a longer time period. The project will only use fertilized eggs of poor quality that, if not used in this study, will be discarded. The cells will not be used for any clinical purpose. After the study is finalized the material will be destroyed. Your participation in this project with material to research is totally voluntary, and you can freely desist from donating material without this in any way influencing your treatment. You can also withdraw your participation in the project at any time.
The initiator of this study is Professor Lars Hamberger, who also is available to answer any questions that concern the embryonic stem cells, their risks and their potential for the future. Phone: 031 – 342 33 38 or e-mail:lars.hamberger@obgyn.gu.se

Further information can be obtained from

Lars Nilsson
Associate Professor
Phone: 031-342 2100, call7893

Christina Bergh
Associate Professor
Phone: 031-342 1000, call 7452

I have verbally been informed about the research and its content and I have taken part of the written information above. I am aware my participation is fully voluntary and that I whenever I wish can without any further explanation can take my donation back without this affecting my further treatment

Date ....

Signature ....

Clarification of signature..... .....

SAHLGRENSKA UNIVERSITY HOSPITAL

Division of Women's Health Care, Urology and Oncology

2001-04-09

You have undergone IVF treatment .....and at that time .....numbers of embryos were frozen down. The time for your storage of frozen embryos will expire within 3-6 months, more specifically the ..... and according to our notes you have not applied for exemption (for longer storage). If no application for exemption is submitted prior the storage deadline then according to the Swedish law we have to destroy your embryos. Since the freezing/storage time is as long as five years, we believe that Socialstyrelsen (The National Board of Health and Welfare) will not grant an exemption as long as not very specific reasons are presented.

An application to Socialstyrelsen shall according to their instructions, be submitted latest two months prior to the expiration of the freeze storage time. The application should be submitted to us two weeks prior so that we can confirm the presence of the frozen embryos.
To facilitate any application for exemption, please state clearly if you have any specific reasons or cause to apply for an exemption.

If we do not receive any exemption application from you prior the stated frozen storage deadline then we will follow the Swedish law and destroy your embryos.

In the event of that you do **not** apply for an exemption we would be very grateful if you could inform us in time and that you inform us if you will allow method development/ research on the embryos prior their destruction or if you do not allow any work to be conducted using your embryos. Please indicate your answer in one of the boxes below. If we get your permission to use your embryos for method development /research then we kindly ask you to read through and sign the attached patient information. The signed patient information form should then be returned back to us together with this signed document (a stamped and addressed envelope is attached).

Göteborg 2001-02-19

Lars Nilsson,
Associate Professor
Division of Women's Health Care/IVF
SU/Sahlgrenska

☐ Are applying for an exemption (please attach copy).

☐ Are **not** applying for exemption. You may destroy our embryos.

☐ Are **not** seeking exemption. We allow research using the embryos prior to destruction (please attach the signed patient information).

Date.....
Signatures.....

This is a translation from the Swedish original presented to the donor couple.
Translated by Mikael Englund, PhD, 2004-10-06

Women's Healthcare, Sahlgrenska University Hospital
Field of activities; Reproductive Medicine

Patient information

Regarding human embryos and the culture of stem cells

In connection to your IVF treatment in 2001, you donated supernumerary embryos for research purposes in the field of stem cell research. The results that have been generated to date or that will be generated in the future as a result of this research on these embryos, for example stem cells, might be used in further research and development of pharmaceutical drugs and methods of treatment of severe widespread diseases. This research includes the use of stem cells for analyses of metabolism and toxicity, as well as directing stem cells towards more mature cells like neural tissue, connective tissue, heart and liver cells, and insulin producing cells. The aim is that such research shall make it possible to treat, and hopefully cure, patients with severe diseases like heart infarction and diabetes, or patients subjected to severe accidents that have generated spinal cord-, or joint injuries.

This research does not only take place in Sweden, but also internationally. We now wish to share the stem cells that have been developed through research on your donated embryos, to stem cell research groups in other countries.

The progressing handling of the stem cells will be in accordance to Swedish law. The cells will be cultured for the time being, and can not be traced back to you by any person not directly concerned, while the key to the code is only available at the Institution for Women's and Children's Health. We hereby ask you if you permit that the stem cells we have developed from the supernumerary embryos you have donated are sent to research groups abroad for the research purposes.

We are grateful if you resend this form after signing.

SAHLGRENSKA UNIVERSITY HOSPITAL
FIELD OF ACTIVITIES; REPRODUCTIVE MEDICINE

Christina Bergh
Professor, Care Unit Chief Physician
Phone: 031-342 23 75

Lars Nilsson
Associated Professor, Chief Physician
Phone: 031-342 13 23

I have been verbally informed about the study and I have read and understood the above written information. I am aware of that my participation in this study is totally voluntarily and that I can, at any time, and without further explanation, terminate my participation, without affecting the medical care given to me.

We permit that these stem cells are sent abroad for research purposes. ☐

We do not permit that these stem cells are sent abroad for research purposes. ☐

We wish to be contacted prior to any new research purpose. ☐

Date.....

Signature.....

Clarification of signature..... social security number.....

Signature.....

Clarification of signature..... social security number.....

Kvinnosjukvården, Sahlgrenska
Verksamhetsområde Reproduktionsmedicin

Patientinformation i samband med donation av mänskliga embryon för odling av s.k. stamceller

Bakgrund och målsättning med studien

Vid provrörsbefruktning erhålls normalt flera befruktade ägg (embryon) än vad som kan återföras till kvinnan vid behandlingstillfället. Om dessa embryon bedöms som normala fryses de för återföring till kvinnan vid ett senare tillfälle om detta skulle bli önskvärt. Embryon som saknar förutsättning att fästa i livmodern - och som därför inte bedöms vara lämpliga att återföra till kvinnan eller som tekniskt inte bedöms klara nedfrysning respektive tining (ej livsdugliga embryon) - förstörs.

Enligt svensk lag får embryon förvaras i fryst tillstånd i fem år. Om paret inte önskar återfå sina frysta embryon inom denna femårsperiod måste dessa embryon förstöras, alternativt doneras till forskning. Sådana frysta embryon, där paret ej önskar återfå dem och där femårsgränsen överskridits, kan doneras till forskning.

Embryon som bedömts som ej livsdugliga samt frysta embryon där femårsgränsen överskridits kan användas för forskningsändamål. Celler från dessa embryon kan utgöra utgångsmaterial för forskning som syftar till odling av stamceller och etablering av stamcellslinjer Man tror idag att sådana stamceller kan utvecklas till exempelvis nervceller, muskelceller och olika typer av blodkroppar. De resultat som framkommer genom forskningen med de överblivna embryonerna, som t.ex. stamcellslinjer, kan sedan komma att användas i forskning och utveckling av läkemedel och behandling av svåra folksjukdomar. Avsikten är att sådan forskning skall möjliggöra behandling av och förhoppningsvis även bota, patienter som drabbats av olyckor såsom ryggmärgs- och ledskador eller sjukdomar såsom bl.a. hjärtinfarkt och diabetes. De till forskningen donerade embryonerna däremot kommer inte att användas för något kliniskt ändamål.

Metod

En del av dessa till forskning donerade embryon kommer att vara möjliga att odla under fem - sex dagar och om man efter denna tidsperiod tar celler från dessa odlade, befruktade ägg så kan cellerna möjligen i nästa steg utvecklas till s.k. stamcellslinjer.

Extra moment som betingas av forskningen

Inga extra moment, vilka direkt berör Dig, görs.

Risker, obehag och biverkningar

Det finns inga ökade risker eller något obehag för Dig.

Fördelar

Du kommer inte direkt att ha några fördelar av att donera material till forskningen. Det finns dock en möjlighet att man i framtiden kan framställa stamceller för transplantation till patienter som drabbats av olika typer av allvarliga sjukdomar.

Sekretesskydd

Materialet kommer att utlämnas till forskare i avidentifierad form, vilket innebär att efter utlämnandet kan materialet inte spåras tillbaks till donatorn.

Frivillighet
Det skall betonas att ditt bidrag med material till forskningen är helt frivilligt. Du kan helt fritt avstå från att donera material utan att detta på något sätt påverkar Din behandling. Du kan även återta Ditt donationsmedgivande fram till att det donerade materialet utlämnats till forskare, då avidentifiering av det donerade materialet sker och spårning av materialet till dig inte längre är möjligt. Du behöver då inte ange någon orsak till avbrytandet och Ditt avbrytande kommer ej heller att påverka Din framtida behandling.

Ekonomisk ersättning
Ekonomisk ersättning utgår inte för deltagande i studien.

Ytterligare information
Om Ni önskar mer information är Ni välkommen att kontakta någon av nedanstående personer.
Denna undersökning sker i samarbete med företaget Cell Therapeutics Scandinavia AB. Företaget finansierar denna forskning huvudsakligen genom att täcka lönen för den personal som är involverad i studien.

SAHLGRENSKA UNIVERSITETSSJUKHUS
VERKSAMHETSOMRÅDE REPRODUKTIONSMEDICIN

Christina Bergh
Professor, vårdenhetsöverläkare
Tfn 031-342 23 75

Lars Nilsson
Docent, överläkare
Tfn 031-342 13 23

Jag har muntligen informerats om forskningen och dess innehåll och tagit del av ovanstående skriftliga information. Jag lämnar här med mitt donationsmedgivande på de villkor och under de förutsättningar som ovan beskrivits. Jag är medveten om att min donation av material för forskningen är fullt frivilligt och att jag när som helst innan avidentifiering av det donerade materialet sker och utan närmare förklaring kan återta mitt donationsmedgivande utan att detta påverkar mitt omhändertagande. Om donationsmedgivandet återtas innan avidentifiering ägt rum kommer det donerade materialet att förstöras och Du kommer att underrättas när så skett.

Datum .....

Namnunderskrift
.....

Namnförtydligande.....person-nr.....

Namnunderskrift
.....

Namnförtydligande.....person-nr.....

Précisions de l'organisme fournisseur (Cellartis AB) concernant les modalités de consentement au don ;

Nous fournissons à l'appui de notre demande des documents, traduits en anglais par le fournisseur lui-même, qui précisaient les modalités de consentement au don. Un document complémentaire du ministère de la santé et des affaires sociales de Suède (en anglais) précisant la position du gouvernement et de la loi Suédoise sur divers aspects de la recherche sur les cellules souches est joint au dossier (government bill 2003/04 :148). La lettre de consentement qui doit être compris et signés par les deux membres du couple donneur précise en particulier les points suivants :

- Les embryons donnés sont des embryons surnuméraires en connexion avec un traitement de fécondation in vitro (projet parental).
- Les embryons surnuméraires sont donnés par les deux membres du couple donneur à des fins de recherche dans le domaine de la recherche sur les cellules souches.
- Dans un deuxième temps les deux membres du couple ont donné spécifiquement leur consentement à ce que les cellules souches issues de la recherche sur les embryons initialement donnés puissent être partagées à des fins de recherche avec des groupes de recherche sur les cellules souches en Suède comme à l'étranger.
- La dérivation et les manipulations des cellules souches se font en accord avec la loi Suédoise et l'origine de l'embryon est codée et ne peut pas être retracée par d'autres personnes que par celles directement concernées. La clé du code d'identification de l'origine des embryons est uniquement détenue par l'institut « Women's and Children's Health ».
- Chaque membre du couple donneur peut à tout moment et sans donner d'explication mettre fin à sa participation au programme sans que cela n'affecte les soins médicaux qui lui sont donnés.

WiCell Cytogenetics Report: 001224-070809
NSCB 1825

Report Date: July 17, 2009

Case Details:

Cell Line: *SA01-DDL-01 (1825)*

Passage #: *22*

Date Completed: *7/17/2009*

Cell Line Gender: *Male*

Investigator: *National Stem Cell Bank*

Specimen: *hESC on MEF feeder*

Date of Sample: *7/8/2009*

Tests,Reason for: *DDL Release Testing and MCB Pre-freeze*

Results: *46,XY*

Completed by , CLSp(CG), on 7/16/2009

Reviewed and interpreted by PhD, FACMG, on 7/17/2009

Interpretation: *No abnormalities were detected at the stated band level of resolution.*



Cell: *S01-05*

Slide: *C*

Slide Type: *Karyotyping*

Cell Results: *Karyotype: 46,XY*

# of Cells Counted: *20*

# of Cells Karyotyped: *5*

# of Cells Analyzed: *9*

Band Level: *450-600*

Results Transmitted by Fax / Email / Post
Sent By: _____
QC Review By: _____

Date: _____
Sent To: _____
Results Recorded: _____

MYCOPLASMA
TESTING SERVICES

BIONIQUE TESTING LABORATORIES, INC

APPENDIX I

Document #:	DCF3008A
Edition #:	06
Effective date:	9/17/2003
Title:	DNA FLUOROCHROME ASSAY RESULTS

DNA-FLUOROCHROME ASSAY RESULTS

Procedures 3008, 3009, 3011

Sample ID # **58277** **M-250** Date Rec'd: **08/06/2009** P.O. #

Indicator Cells Inoculated: Date/Initials: 8/6/09 / BMB

Fixation: Date/Initials: 8/10/09 / JA

Staining: Date/Initials: 8/10/09 / JA

TEST/CONTROL ARTICLE:

SA01 DDL 1 6-~~P27~~ P27 NSCB#3125

SA 9-2-09

LOT# **NA**

Wicell QA
WiCell Research Institute

DNA FLUOROCHROME ASSAY RESULTS:

__X__ **NEGATIVE:** A reaction with staining limited to the nuclear region, which indicates no mycoplasmal contamination.

_____ **POSITIVE:** A significant amount of extranuclear staining which strongly suggests mycoplasmal contamination.

_____ **INCONCLUSIVE:**

_____ A significant amount of extranuclear staining consistent with low - level mycoplasmal contamination or nuclear degeneration.

_____ A significant amount of extranuclear staining consistent with bacterial, fungal or other microbial contaminant or viral CPE. Morphology not consistent for mycoplasmal contamination.

COMMENTS: _____

Date: 8/10/09 Results Read by: JA Date of Review: 8-10-09 Reviewed by: SeA

Document#: DCF3013D
Edition#: 10
Effective Date: 07/15/2003
Title: M-250 FINAL REPORT SHEET

SAMPLE ID#: 58277		AEROBIC	MICROAEROPHILIC	DATE
AGAR PLATES-FORTIFIED COMMERCIAL	DAY 7	+	+	08/13/2009
	DAY 14	+	+	08/20/2009
	DAY 21	+	+	08/27/2009
AGAR PLATES-MODIFIED HAYFLICK	DAY 7	+	+	08/13/2009
	DAY 14	+	+	08/20/2009
	DAY 21	+	+	08/27/2009
AGAR PLATES-HEART INFUSION	DAY 7	+	+	08/13/2009
	DAY 14	+	+	08/20/2009
	DAY 21	+	+	08/27/2009
BROTH SUBCULTURES (DAY 7)		DATE: 08/13/2009		
AGAR PLATES-FORTIFIED COMMERCIAL	DAY 7	+	+	08/20/2009
	DAY 14	+	+	08/27/2009
	DAY 21	+	+	09/03/2009
AGAR PLATES-MODIFIED HAYFLICK	DAY 7	+	+	08/20/2009
	DAY 14	+	+	08/27/2009
	DAY 21	+	+	09/03/2009
AGAR PLATES-HEART INFUSION	DAY 7	+	+	08/20/2009
	DAY 14	+	+	08/27/2009
	DAY 21	+	+	09/03/2009

RESULTS: No detectable mycoplasmal contamination

9/3/09
Date

Laboratory Director
Ph.D.

M-250 Procedural Summary: The objective of this test is to ascertain whether or not detectable mycoplasmas are present in an in vitro cell culture sample, be it a primary culture, hybridoma, master seed stock or cell line. This procedure combines an indirect DNA staining approach to detect non-cultivable mycoplasmas with a direct culture methodology utilizing three different mycoplasmal media formulations. The indirect approach involves the inoculation of the sample into a mycoplasma-free VERO (ATCC) indicator cell line and performing a DNA fluorochrome assay after 72-120 hours of incubation. The direct culture aspect of the test utilizes three different mycoplasmal media including both broth and agar formulations. The sample is inoculated into each of the 3 broth formulations and also onto duplicate plates (0.1 mL/plate) for each of the 3 agar formulations. Subculture from broth to fresh agar plates is carried out after 7 days incubation. Agar plates are incubated aerobically and microaerophillically in order to detect any colony forming units morphologically indicative of mycoplasmal contamination. Issuance of the final report with signature of the Laboratory Director signifies that the required controls were performed concurrently with the test sample(s) as detailed in the referenced SOPs and that all test conditions have been found to meet the required acceptance criteria for a valid test, including the appropriate results for the positive and negative controls.

Mycoplasma Testing Services Safe Cells

BIONIQUE TESTING LABORATORIES, INC.

APPENDIX IV

Document#: DCF3013D
Edition#: 10
Effective Date: 07/15/2003
Title: **M-250 FINAL REPORT SHEET**

M-250 FINAL REPORT

Direct Specimen Culture
Procedure 3008, 3011, 3013

TO: Wicell QA
WiCell Research Institute

BTL SAMPLE ID#: **58277** P.O.#: DATE REC'D: **08/06/2009**

TEST/CONTROL ARTICLE:

SA01 DDL 1 6 p27 NSCB#3125

LOT#: **NA**

DIRECT CULTURE SET-UP (DAY 0) DATE: **08/06/2009**

INDICATOR CELL LINE (VERO) SEE DNA FLUOROCHROME RECORD SHEET

			DATE
THIOGLYCOLLATE BROTH	DAY 7	+	08/13/2009
	DAY 28	+	09/03/2009
BROTH-FORTIFIED COMMERCIAL			
0.5 mL SAMPLE	DAY 7	+	08/13/2009
6.0 mL BROTH	DAY 28	+	09/03/2009
BROTH-MODIFIED HAYFLICK			
0.5 mL SAMPLE	DAY 7	+	08/13/2009
6.0 mL BROTH	DAY 28	+	09/03/2009
BROTH-HEART INFUSION			
0.5 mL SAMPLE	DAY 7	+	08/13/2009
6.0 mL BROTH	DAY 28	+	09/03/2009

(See Reverse)

UW Health

University of Wisconsin
Hospital and Clinics

Histocompatibility/Molecular Diagnostics Laboratory

Short Tandem Repeat Analysis*

Sample Report: 3125-STR | UW HLA#: 61995 | Sample Date: 11/06/09, Received Date: 11/06/09

Requestor: WiCell Research Institute

Test Date: 11/09/09 | File Name: 091110 | Report Date: 11/12/09

Sample Name: (label on tube) **3125-STR**

Description: DNA Extracted by WiCell 310.7 ug/mL; 260/280 = 1.86

Locus	Repeat #	STR Genotype
D16S539	5, 8-15	12,13
D7S820	6-14	8,10
D13S317	7-15	11,12
D5S818	7-15	12,13
CSF1PO	6-15	10,13
TPOX	6-13	8,9
Amelogenin	NA	X,Y
TH01	5-11	9.3,9.3
vWA	11, 13-21	16,18

Comments: Based on the 3125-STR DNA dated and received on 11/06/09 from WI Cell, this sample (UW HLA# 61995) matches exactly the STR profile of the human stem cell line SA01 comprising 15 allelic polymorphisms across the 8 STR loci analyzed. No STR polymorphisms other than those corresponding to the human SA01 stem cell line were detected and the concentration of DNA required to achieve an acceptable STR genotype (signal/noise) was equivalent to that required for the standard procedure (~1 ng/amplification reaction) from human genomic DNA. These results suggest that the 3125-STR DNA sample submitted corresponds to the SA01 stem cell line and it was not contaminated with any other human stem cells or a significant amount of mouse feeder layer cells. Sensitivity limits for detection of STR polymorphisms unique to either this or other human stem cell lines is ~5%.

11-17-09

, Manager Date
HLA/Molecular Diagnostics Laboratory

11/12/09

PhD, Director Date
HLA/Molecular Diagnostics Laboratory

* Testing to assess engraftment following bone marrow transplantation was accomplished by analysis of human genetic polymorphisms at STR loci. This methodology has not yet been approved by the FDA and is for investigational use only.

File: Final STR Report

Certificate of Analysis - Amended

Depositor Distribution Lot

Product Description	(SA01) Depositor Distribution Lot
Cell Line Provider	Cellartis
Distribution Lot Number	SA01-DDL-01[1]
Date Vialed	[2]
Passage Number	[3]

The following testing specifications have been met for the specified product lot:

Test Description	Test Method	Test Specification	Result
Post-Thaw Viable Cell Recovery	SOP-CH-305C	Viable cells recovered	Pass
Identity by STR	SOP-SS-006B	Positive identity	Pass
Mycoplasma	Bionique Method M250	No contamination detected	Pass
Karyotype by G-banding	SOP-CH-003B	Normal karyotype	Pass

Cells distributed by the National Stem Cell Bank are intended for research purposes only and are not intended for use in humans.

Electronic versions lot certificates (CoAs) complete with electronic copies of individual reports, results, and procedures are available on our website, www.wicell.org. There are also archived CoAs for past cell lots.

Please visit the technical service portion of the website for assistance with your human ES Cells. The knowledgeable technical support staff can assist with embryonic stem cell culture concerns, training, and any other customer service concerns you may encounter.

Amendment(s):

Reason for Amendment	Date
CoA updated to include copyright information and electronic signature, and update to WiCell logo. Links updated.	See signature
Original CoA	23-Dec-2009

Date of Lot Release	Quality Assurance Approval
23-December-2009	1/3/2014 X AMC AMC Quality Assurance Signed by: [redacted]

[1] This material is Cellartis Lot CA001 and does not represent a lot of material grown by the NSCB. The test results shown on this CoA is to supplement the testing done by the provider.
[2] See Cellartis CoA for date vialed.
[3] See Cellartis CoA for passage number

Cell Line: SA01
Lot: CA001

Table of Contents

This material was cultured and frozen using Cellartis' protocols. WiCell recommends that stem cells should be thawed and established in the conditions in which they were initially frozen prior to transfer to alternate culture platforms. The protocols that were used to produce these cells can be found on the following pages of this document.

If you have any questions or concerns please contact WiCell's technical support staff via our website side at www.wicell.org and we will be happy to assist you.

Thank you,

WiCell

P.O Box 7365 • Madison, WI 53707-7365 • Phone: 888.204.1782 • Fax: 608.441.8011
www.wicell.org

Direction juridique

Dossier suivi par Thomas VAN DEN HEUVEL
Tel. : 01 55 93 64 83
Fax : 01 55 93 64 51
Thomas.vandenheuvel@biomedecine.fr

LRAR

La Directrice générale

à

Monsieur Yann GUIVARCH
CECS/I-STEM
CRCT-CECS/I-STEM
28 rue Henri Desbruères
91100 CORBEIL ESSONNES

yguivarch@istem.fr

Saint-Denis, le 1er juillet 2022

ACCUSE DE RECEPTION
Déclaration d'une conservation de cellules souches embryonnaires humaines
(article L. 2151-9 du code de la santé publique)

Vous avez adressé à l'Agence de la biomédecine le 22 juin dernier une déclaration de conservation de cellules souches embryonnaires humaines, placée sous la responsabilité de M. Marc Peschanski et Mme Alexandra Benchoua.

Cette déclaration, enregistrée sous le n° **DE22-004C,** est en la forme recevable et complète.

Cette activité peut être entreprise à réception du présent courrier.

Je vous informe qu'en cas de violation des exigences législatives et réglementaires, je peux à tout moment vous mettre en demeure de mettre fin aux manquements constatés et, le cas échéant, de présenter vos observations dans un délai que je fixerai. Si les mesures prises ne sont pas de nature à mettre un terme à ces manquements, je peux également suspendre ou interdire l'activité de conservation de cellules souches embryonnaires qui ne répondrait plus aux exigences fixées par le législateur à l'article L. 2151-9 du code de la santé publique.

Je vous prie d'agréer, Monsieur, l'assurance de ma considération distinguée.

Pour la directrice générale et par délégation,

Anne DEBEAUMONT
Directrice juridique